MARKET

LIFE

LIFE

Atyr Pharma Inc
NASDAQ
1.950
-0.050
-2.50%
After Hours: 1.969 +0.019 +0.99% 18:55 03/28 EDT
OPEN
2.040
PREV CLOSE
2.000
HIGH
2.050
LOW
1.890
VOLUME
726.17K
TURNOVER
0
52 WEEK HIGH
2.700
52 WEEK LOW
1.080
MARKET CAP
132.11M
P/E (TTM)
-2.0745
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LIFE last week (0318-0322)?
Weekly Report · 3d ago
WW, ATNM and XTIA are among pre market gainers
On the Move WW, ATNM and XTIA are among pre market gainers. Fusion Pharmaceuticals (FUSN) will buy Fusion pharmaceuticals for $2B. SCWorx (WORX) is up 18%. National Cinemedia (NCMI) gains 25%.
Seeking Alpha · 03/19 12:04
Weekly Report: what happened at LIFE last week (0311-0315)?
Weekly Report · 03/18 10:15
3 Best Stocks to Buy Now, 3/18/2024, According to Top Analysts 
According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well. Jabil, Applied Digital Corporation and Life Pharma are among today's top stock picks, according to analysts. TipRanks ranks financial analysts according to the accuracy of their ratings.
TipRanks · 03/18 06:05
aTyr Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 03/15 16:59
aTyr Pharma Price Target Cut to $16.00/Share From $19.00 by RBC Capital
Dow Jones · 03/15 16:59
RBC Capital Maintains Outperform on aTyr Pharma, Lowers Price Target to $16
Benzinga · 03/15 16:49
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
TipRanks · 03/15 10:50
More
About LIFE
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.